PEG-GRQDs, conjugated with herceptin (HER) and DOX-loaded β-cyclodextrin, were designed by Ko et al. [103], for the treatment of human epidermal growth-factor receptor 2 (HER2)-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.